Cargando…

Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation

Magnesium (Mg) contributes to DNA stability, protein synthesis and cardiac excitability, while Mg deficiency leads to increased cardiovascular mortality, diabetes, hyperparathyroidism and risk of fractures. In kidney transplant patients, calcineurin inhibitors (CNIs) downregulating Mg channel TRPM6...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanelli, Lucia Federica, Alessi, Marianna, Bertoldi, Giovanni, Rossato, Valentina, Di Vico, Valentina, Nalesso, Federico, Calò, Lorenzo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917957/
https://www.ncbi.nlm.nih.gov/pubmed/36769401
http://dx.doi.org/10.3390/jcm12030752
_version_ 1784886494259838976
author Stefanelli, Lucia Federica
Alessi, Marianna
Bertoldi, Giovanni
Rossato, Valentina
Di Vico, Valentina
Nalesso, Federico
Calò, Lorenzo A.
author_facet Stefanelli, Lucia Federica
Alessi, Marianna
Bertoldi, Giovanni
Rossato, Valentina
Di Vico, Valentina
Nalesso, Federico
Calò, Lorenzo A.
author_sort Stefanelli, Lucia Federica
collection PubMed
description Magnesium (Mg) contributes to DNA stability, protein synthesis and cardiac excitability, while Mg deficiency leads to increased cardiovascular mortality, diabetes, hyperparathyroidism and risk of fractures. In kidney transplant patients, calcineurin inhibitors (CNIs) downregulating Mg channel TRPM6 in the distal collecting tubule induce early hypomagnesemia (HypoMg), which is associated with a faster decline in allograft function. A new formulation, sucrosomial Mg (SucrMg), for oral supplements encapsulates Mg oxide in a phospholipid membrane covered by a sucrester matrix, enhancing gastric and intestinal Mg absorption. This study has evaluated Mg bioavailability, effectiveness and tolerance of SucrMg compared to the conventional preparation of Mg pidolate (PidMg). The association of blood Mg with risk of post-transplant dysglycemia and hyperparathyroidism has also been investigated. Forty hypomagnesemic adult single, double or combined kidney–pancreas or kidney–liver transplant recipients within 2 years from transplantation were recruited. In total, 16 patients received PidMg and 27 received SucrMg. Blood Mg was measured at baseline (T0), after 15 days (T1) and after 6 months (T2) of treatment. PTH, fasting glucose and calcium were measured at baseline and after 6 months of treatment. The tolerance was evaluated at the ambulatory visits. SucrMg compared to PidMg was more efficient at increasing Mg bioavailability at T1: p < 0.0001 vs. p = 0.72 ns, respectively, with a ∆% increase of 12.4% vs. 5.4%, p = 0.04. Both preparations increased blood Mg at T2, p < 0.0001 and p = 0.002, respectively. SucrMg was better tolerated. No difference was observed for fasting plasma glucose, PTH and calcium. On one hand, our study is the first among transplant patients to evaluate the efficacy of SucrMg in the correction of HypoMg, which might justify the limited number of patients enrolled and the short observation time; on the other hand, our results could serve as a useful working hypothesis for further studies with a larger number of transplant patients and an extended study duration to confirm the benefits observed with SucrMg.
format Online
Article
Text
id pubmed-9917957
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99179572023-02-11 Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation Stefanelli, Lucia Federica Alessi, Marianna Bertoldi, Giovanni Rossato, Valentina Di Vico, Valentina Nalesso, Federico Calò, Lorenzo A. J Clin Med Article Magnesium (Mg) contributes to DNA stability, protein synthesis and cardiac excitability, while Mg deficiency leads to increased cardiovascular mortality, diabetes, hyperparathyroidism and risk of fractures. In kidney transplant patients, calcineurin inhibitors (CNIs) downregulating Mg channel TRPM6 in the distal collecting tubule induce early hypomagnesemia (HypoMg), which is associated with a faster decline in allograft function. A new formulation, sucrosomial Mg (SucrMg), for oral supplements encapsulates Mg oxide in a phospholipid membrane covered by a sucrester matrix, enhancing gastric and intestinal Mg absorption. This study has evaluated Mg bioavailability, effectiveness and tolerance of SucrMg compared to the conventional preparation of Mg pidolate (PidMg). The association of blood Mg with risk of post-transplant dysglycemia and hyperparathyroidism has also been investigated. Forty hypomagnesemic adult single, double or combined kidney–pancreas or kidney–liver transplant recipients within 2 years from transplantation were recruited. In total, 16 patients received PidMg and 27 received SucrMg. Blood Mg was measured at baseline (T0), after 15 days (T1) and after 6 months (T2) of treatment. PTH, fasting glucose and calcium were measured at baseline and after 6 months of treatment. The tolerance was evaluated at the ambulatory visits. SucrMg compared to PidMg was more efficient at increasing Mg bioavailability at T1: p < 0.0001 vs. p = 0.72 ns, respectively, with a ∆% increase of 12.4% vs. 5.4%, p = 0.04. Both preparations increased blood Mg at T2, p < 0.0001 and p = 0.002, respectively. SucrMg was better tolerated. No difference was observed for fasting plasma glucose, PTH and calcium. On one hand, our study is the first among transplant patients to evaluate the efficacy of SucrMg in the correction of HypoMg, which might justify the limited number of patients enrolled and the short observation time; on the other hand, our results could serve as a useful working hypothesis for further studies with a larger number of transplant patients and an extended study duration to confirm the benefits observed with SucrMg. MDPI 2023-01-17 /pmc/articles/PMC9917957/ /pubmed/36769401 http://dx.doi.org/10.3390/jcm12030752 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stefanelli, Lucia Federica
Alessi, Marianna
Bertoldi, Giovanni
Rossato, Valentina
Di Vico, Valentina
Nalesso, Federico
Calò, Lorenzo A.
Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation
title Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation
title_full Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation
title_fullStr Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation
title_full_unstemmed Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation
title_short Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation
title_sort calcineurin-inhibitor-induced hypomagnesemia in kidney transplant patients: a monocentric comparative study between sucrosomial magnesium and magnesium pidolate supplementation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917957/
https://www.ncbi.nlm.nih.gov/pubmed/36769401
http://dx.doi.org/10.3390/jcm12030752
work_keys_str_mv AT stefanelliluciafederica calcineurininhibitorinducedhypomagnesemiainkidneytransplantpatientsamonocentriccomparativestudybetweensucrosomialmagnesiumandmagnesiumpidolatesupplementation
AT alessimarianna calcineurininhibitorinducedhypomagnesemiainkidneytransplantpatientsamonocentriccomparativestudybetweensucrosomialmagnesiumandmagnesiumpidolatesupplementation
AT bertoldigiovanni calcineurininhibitorinducedhypomagnesemiainkidneytransplantpatientsamonocentriccomparativestudybetweensucrosomialmagnesiumandmagnesiumpidolatesupplementation
AT rossatovalentina calcineurininhibitorinducedhypomagnesemiainkidneytransplantpatientsamonocentriccomparativestudybetweensucrosomialmagnesiumandmagnesiumpidolatesupplementation
AT divicovalentina calcineurininhibitorinducedhypomagnesemiainkidneytransplantpatientsamonocentriccomparativestudybetweensucrosomialmagnesiumandmagnesiumpidolatesupplementation
AT nalessofederico calcineurininhibitorinducedhypomagnesemiainkidneytransplantpatientsamonocentriccomparativestudybetweensucrosomialmagnesiumandmagnesiumpidolatesupplementation
AT calolorenzoa calcineurininhibitorinducedhypomagnesemiainkidneytransplantpatientsamonocentriccomparativestudybetweensucrosomialmagnesiumandmagnesiumpidolatesupplementation